Full Prescribing Information
Important Safety Information
Mechanism of Action
Dosing and Application
The LATISSE® Patient
LATISSE® In My Practice
Review how lashes may thin with age and the role of LATISSE® in treating hypotrichosis
Visit the before-and-after
Download logos, before-and-after photos, andother educational tools
LATISSE® (bimatoprost ophthalmic solution) 0.03%
is indicated to treat hypotrichosis of the eyelashes by increasing their growth,
including length, thickness, and darkness.
Warnings and Precautions: In patients using LUMIGAN®
(bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment
of elevated intraocular pressure (IOP), the concomitant use of LATISSE®
may interfere with the desired reduction in IOP. Patients using prostaglandin analogs
including LUMIGAN® for IOP reduction should only
use LATISSE® after consulting with their physician
and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered.
Patients should be advised about the potential for increased brown iris pigmentation,
which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital
pigmented tissues and eyelashes.
There is the potential for hair growth to occur in areas where LATISSE®
solution comes in repeated contact with skin surfaces. Apply LATISSE®
only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in
patients with active intraocular inflammation (eg, uveitis) because the inflammation
may be exacerbated.
LATISSE® contains benzalkonium chloride, which may
be absorbed by soft contact lenses. Contact lenses should be removed prior to application
of solution and may be reinserted 15 minutes following its administration.
Adverse Reactions: The most frequently reported adverse events
were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation,
dry eye symptoms, and erythema of the eyelid. These events occurred in less than
4% of patients.
Postmarketing Experience: The following reactions have been identified
during postmarketing use of LATISSE® in clinical
practice: burning sensation (eyelid), erythema periorbital, eye swelling, eyelid
irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation, lacrimation increased,
madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections
of eyelashes, and temporary eyelash breakage, respectively), rash (including macular,
erythematous, and pruritic limited to the eyelids and periorbital region), skin
discoloration (periorbital), and vision blurred.
Use in Specific Populations: Use in pediatric patients below the
age of 16 years is not recommended because of potential safety concerns related
to increased pigmentation following long-term chronic use.
Click here for full Prescribing Information.
BOTOX® Cosmetic (onabotulinumtoxinA) Important Information
BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with
corrugator and/or procerus muscle activity in patients 18 to 65 years of age.
Distant Spread of Toxin Effect
LATISSE® Prescribing Information.
All women featured on this website are paid LATISSE® patients.
Home | Patient Site |
Full Prescribing Information |
| Contact Allergan
©2012 Allergan, Inc., Irvine, CA 92612 ® and ™ marks owned
by Allergan, Inc.
www.latisse.com APC35ME12 121201